A dirt-cheap FTSE 100 dividend stock I’d buy for my ISA and hold until 2029

Attention FTSE 100 investors! This is a dividend stock worth buying now and holding for the next 10 years, says Royston Wild.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A FTSE 100 stock I reckon is a great pick for novice share pickers and experienced equity investors alike is The Berkeley Group (LSE: BKG).

I’m not going to pretend that everything is fine and dandy over at the blue-chip housebuilder. Brexit fears continue to crimp buyer activity in its core markets of London and the South East, geographies where property prices have long been accused of being severely overheated. Current political and economic uncertainty means that homebuyers are thinking twice before taking the plunge, but I believe this will end up being a short-lived phenomenon.

London calling

Make no mistake: these regions in the south of England are the engine room of the UK economy, and in the case of London, a market that has been popular with both residential owners and investors for centuries. Once the current political deadlock around Brexit is broken I expect buying activity to pick up at Berkeley, and fast.

Besides, it’s not as if business conditions at Berkeley are sinking at an alarming rate. In its most recent trading statement of 6 September the construction colossus advised that “market conditions in London and the South East have remained robust” in the first four months of the current financial year, the business adding that “pricing has remained stable and the group’s forward sales position remains above £1.8bn.”

City analysts, then, expect the builder to return to earnings growth in the next financial year with a 2% bottom-line advance. Decent dividend yields of 3.8% and 4% for the fiscal periods to April 2020 and 2021 provide plenty to get excited about, too. And a low forward price-to-earnings ratio of 14.1 times, despite its recent ascent to record highs around £47.80, gives long-term investors an attractive entry point to buy in.

The right medicine

Before you go I’d like to shine a light on AstraZeneca (LSE: AZN), another brilliant Footsie share with the wind in its sails right now. Its share price has recently crept back towards the record closing highs of £75.80 of late October, and despite its elevated forward P/E ratio of 27 times I expect it to hit new peaks sooner rather than later.

In my book pharmaceuticals star AstraZeneca is every inch a stock worthy of a hefty premium to the broader FTSE 100 (where the broader forward average sits closer to 15 times). I recently celebrated the strength of the company’s pipeline of new treatments and newsflow since then has reinforced my enthusiasm.

A string of positive testing and regulatory updates in recent weeks includes the approval of its Qtrilmet diabetes battler in Europe, and US lawmakers granting fast-track review status for its selumetinib drug for the treatment of neurofibromatosis type 1 in children. AstraZeneca’s new product lineup is already lighting a fire under the bottom line, causing City analysts to predict that the 4% earnings rise for 2019 will improve to 19% next year. And this recent news gives commentators more reason to be cheery about the business for well into the next decade.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Why Warren Buffett fears AI – and where savvy investors could spot an opportunity

Warren Buffett is cautious about AI but this Fool thinks the technology could present unique opportunities for forward-thinking investors.

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Is the 12.3% yield on this UK dividend stock too good to be true?

The impressive double-digit yield on this dividend stock recently grabbed the attention of our writer. But how sustainable is it?

Read more »

Investing Articles

2 dividend growth stocks analysts think are strong buys right now

Growth stocks that also distribute cash offer investors the best of both worlds. Stephen Wright looks at two that have…

Read more »

Investing Articles

I asked Anthropic’s Claude for the best FTSE 100 stock to buy right now. I’m impressed with what it said

Can artificial intelligence identify the best FTSE 100 stock to buy right now? Stephen Wright tried it out – and…

Read more »

Investing Articles

£1k in savings? Here’s how investors can aim to turn that into a £9,600-a-year second income

Harvey Jones invests small, regular sums in FTSE 100 dividend stocks in an attempt to build a second income stream…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

5 investment trusts to consider for a new 2025 ISA

The biggest challenge when starting an ISA is choosing which stocks to buy. Investment trusts can make it a whole…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Have I left it too late to buy Nvidia shares?

When the whole world was racing to buy Nvidia shares, Harvey Jones decided they were overhyped. Does the recent dip…

Read more »

Dividend Shares

I asked ChatGPT to pick me the best passive income stock. Here’s the result!

Jon Smith tries to make friends with ChatGPT and critiques the best passive income pick the AI tool suggested for…

Read more »